Emavusertib
As of the edition of 20 October 2026, Emavusertib is a small molecule: stopped in 2026; acts on IRAK4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 12, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Immune system; Nervous system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IRAK4 | Interleukin-1 receptor-associated kinase 4 | Q9NWZ3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 0 | 4 | 0 |
| Phase 2 | 7 | 0 | 4 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Curis | Lead sponsor of trials | 2017 to now |